Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study.

Omvoh (mirikizumab-mrkz) - Eli Lilly

Entyvio (vedolizumab) - Takeda

http://www.ncbi.nlm.nih.gov/pubmed/42712747

Asaf Levartovsky; Chaya Mushka Abitbol; Martin Lukáš; Milan Lukáš; Shomron Ben-Horin; Uri Kopylov

Sep 10, 2026